U.S. Department of Health & Human Services (HHS) just finalized its rules requiring pharmaceutical companies to list drug prices in their TV ads this summer.
We could look at this as a blow to pharmaceutical and biotech stocks. But it's also a huge catalyst for cannabis stocks going toe to toe with Big Pharma.
One cannabis stock in particular is already expecting more than 200% sales growth this year, and this could be the catalyst it needs to start its next rally.
This rule is the culmination of the president's "American Patients First" initiative, geared at increasing transparency and bringing down drug prices for both patients and Medicare/Medicaid.
News 
Market Data 
Discover 
